About Collaborating With Us
The Immune Tolerance Network (ITN) is an international clinical research consortium sponsored by NIAID, part of the National Institutes of Health, whose mission is to accelerate the clinical development of immune tolerance therapies through a unique development model.
More than just a funding source...
The ITN development model is a highly interactive process that capitalizes on our wide-ranging, multidisciplinary expertise, provided by an advisory board of highly respected faculty from institutions worldwide. It begins with the application process - from pre- and post-application support, to formal Q&A sessions with reviewers, we help investigators develop high quality research studies. For more information about the application process, contact Philip Bernstein, Executive Director of Strategic Review and Planning.
More than clinical trials...
The ITN looks beyond the traditional clinical trial endpoints of safety and efficacy, actively investigating the mechanisms of tolerance induction and maintenance, integrating hypothesis-driven, mechanism-based research into all its clinical trials. In addition to clinical efficacy, the ITN is seeking to define new biomarkers of tolerance in human disease. Supported by an unprecedented array of core facilities offering state-of-the-art genetic, cellular and immunologic assays, the ITN is generating some of the first combined clinical and mechanistic data on immune tolerance induction in humans. View our clinical trials.
A platform for innovation...
In the ITN's unique hybrid academic/industry model, academia, government and industry all play a vital role in the conduct and planning of clinical studies. With a flexible partnership model, the ITN seeks to create a synergy between partners to help each meet their research goals. If you have questions or want more information, please contact the Immune Tolerance Network.